{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T02:44:42Z","timestamp":1749005082542,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1038\/s41375-022-01583-4","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T04:03:53Z","timestamp":1652414633000},"page":"1818-1824","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Co-variates associated with outcomes of tyrosine kinase-inhibitor therapy in persons with chronic myeloid leukaemia initially presenting in accelerated phase"],"prefix":"10.1038","volume":"36","author":[{"given":"Sen","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5405-0802","authenticated-orcid":false,"given":"Xiao-shuai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-1676","authenticated-orcid":false,"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-6643","authenticated-orcid":false,"given":"Xiao-jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7131-0522","authenticated-orcid":false,"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"key":"1583_CR1","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/leu.2015.73","volume":"29","author":"VS Hoffmann","year":"2015","unstructured":"Hoffmann VS, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D, et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia. 2015;29:1336\u20131343.","journal-title":"Leukemia"},{"key":"1583_CR2","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/ajh.25628","volume":"94","author":"M Lauseker","year":"2019","unstructured":"Lauseker M, Bachl K, Turkina A, Faber E, Prejzner W, Olsson-Str\u00f6mberg U, et al. Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin. Am J Hematol. 2019;94:1236\u20131243.","journal-title":"Am J Hematol"},{"key":"1583_CR3","doi-asserted-by":"publisher","unstructured":"Ohanian M, Kantarjian HM, Shoukier M, Dellasala S, Musaelyan A, Nogueras Gonzalez GM, et al. The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia. Am J Hematol. 2020;10.1002\/ajh.25907. https:\/\/doi.org\/10.1002\/ajh.25907 [published online ahead of print].","DOI":"10.1002\/ajh.25907"},{"key":"1583_CR4","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041\u20136051.","journal-title":"J Clin Oncol"},{"key":"1583_CR5","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872\u2013884.","journal-title":"Blood"},{"key":"1583_CR6","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809\u20131820.","journal-title":"Blood"},{"key":"1583_CR7","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u2013984.","journal-title":"Leukemia"},{"key":"1583_CR8","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","volume":"18","author":"MW Deininger","year":"2020","unstructured":"Deininger MW, Shah NP, Altman JK, Berman E, Bhatia R, Bhatnagar B, et al. Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2020;18:1385\u20131415.","journal-title":"J Natl Compr Cancer Netw"},{"key":"1583_CR9","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/bjh.15453","volume":"182","author":"YZ Qin","year":"2018","unstructured":"Qin YZ, Jiang Q, Jiang H, Lai YY, Shi HX, Chen WM, et al. Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre. Br J Haematol. 2018;182:693\u2013700.","journal-title":"Br J Haematol"},{"key":"1583_CR10","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.leukres.2013.06.003","volume":"37","author":"YZ Qin","year":"2013","unstructured":"Qin YZ, Jiang Q, Jiang H, Li JL, Li LD, Zhu HH, et al. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level? Leuk Res. 2013;37:1035\u20131040.","journal-title":"Leuk Res"},{"key":"1583_CR11","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","volume":"109","author":"F Guilhot","year":"2007","unstructured":"Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007;109:4143\u20134150.","journal-title":"Blood"},{"key":"1583_CR12","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.jclinepi.2015.01.002","volume":"68","author":"G Mnatzaganian","year":"2015","unstructured":"Mnatzaganian G, Davidson DC, Hiller JE, Ryan P. Propensity score matching and randomization. J Clin Epidemiol. 2015;68:760\u2013768.","journal-title":"J Clin Epidemiol"},{"key":"1583_CR13","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","volume":"57","author":"V Sundararajan","year":"2004","unstructured":"Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004;57:1288\u20131294.","journal-title":"J Clin Epidemiol"},{"key":"1583_CR14","doi-asserted-by":"publisher","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","volume":"10","author":"RL Camp","year":"2004","unstructured":"Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252\u20137259.","journal-title":"Clin Cancer Res"},{"key":"1583_CR15","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127:2391\u20132405. Blood 2016 Jul 21; 128(3): 462-463.","journal-title":"Blood"},{"key":"1583_CR16","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1002\/1097-0142(19880401)61:7<1441::AID-CNCR2820610727>3.0.CO;2-C","volume":"61","author":"HM Kantarjian","year":"1988","unstructured":"Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988;61:1441\u20131446.","journal-title":"Cancer"},{"key":"1583_CR17","first-page":"49","volume":"25","author":"JE Sokal","year":"1988","unstructured":"Sokal JE, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol. 1988;25:49\u201361.","journal-title":"Semin Hematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01583-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01583-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01583-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T07:23:53Z","timestamp":1656919433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01583-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1583"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01583-4","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"type":"print","value":"0887-6924"},{"type":"electronic","value":"1476-5551"}],"subject":[],"published":{"date-parts":[[2022,5,13]]},"assertion":[{"value":"28 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RPG is a consultant to BeiGene Ltd., Fusion Pharma LLC, LaJolla NanoMedical Inc., Mingsight Parmaceuticals Inc. and CStone Pharmaceuticals; advisor to Antegene Biotech LLC, Medical Director, FFF Enterprises Inc.; partner, AZAC Inc.; Board of Directors, Russian Foundation for Cancer Research Support; and Scientific Advisory Board: StemRad Ltd.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Approve by the Ethics Committee of People\u2019s Hospital Beijing compliant with precepts the Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}